Literature DB >> 19105203

An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3.

Todd L Edwards1, Margaret Pericak-Vance, Johnny R Gilbert, Jonathan L Haines, Eden R Martin, Marylyn D Ritchie.   

Abstract

Alzheimer's disease (AD) is the most common form of progressive dementia in the elderly. It is a neurodegenerative disorder characterized by the neuropathologic findings of neurofibrillary tangles and amyloid plaques that accumulate in vulnerable brain regions. AD etiology has been studied by many groups, but since the discovery of the APOE epsilon4 allele, no further genes have been mapped conclusively to late-onset AD (LOAD). In this study, we examined genetic association with LOAD susceptibility in 738 Caucasian families (4,704 individuals) and an independent case-control dataset with 296 cases and 566 controls exploring 11 candidate genes (47 SNPs common to both samples). In addition to tests for main effects and haplotypes, the MDR-PDT was used to search for gene-gene interactions in the family data. We observed significant haplotype effects in ACE in family and case-control samples using standard and cladistic haplotype models. ACE was also part of significant 2 and 3-locus MDR-PDT joint effects models with Alpha-2-Macroglobulin (A2M), which mediates the clearance of Abeta, and Leucine-Rich Repeat Transmembrane-3 (LRRTM3), a nested gene in Alpha-3 Catenin (CTNNA3) which binds Presenilin-1. This result did not replicate in the case-control sample, and may not be a true positive. These genes are related to Abeta clearance; thus this constellation of effects might constitute an axis of susceptibility for LOAD. The consistent ACE haplotype result between independent family-based and unrelated case-control datasets is strong evidence in favor of ACE as a susceptibility locus for AD, and replicates results from several other studies in a large sample. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19105203      PMCID: PMC2821734          DOI: 10.1002/ajmg.b.30899

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  97 in total

1.  A test for linkage and association in general pedigrees: the pedigree disequilibrium test.

Authors:  E R Martin; S A Monks; L L Warren; N L Kaplan
Journal:  Am J Hum Genet       Date:  2000-05-23       Impact factor: 11.025

2.  Testing linkage disequilibrium in sibships.

Authors:  K D Siegmund; B Langholz; P Kraft; D C Thomas
Journal:  Am J Hum Genet       Date:  2000-05-30       Impact factor: 11.025

3.  Fine-mapping of an ancestral recombination breakpoint in DCP1.

Authors:  M Farrall; B Keavney; C McKenzie; M Delépine; F Matsuda; G M Lathrop
Journal:  Nat Genet       Date:  1999-11       Impact factor: 38.330

4.  Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population.

Authors:  J Hu; F Miyatake; Y Aizu; H Nakagawa; S Nakamura; A Tamaoka; R Takahash; K Urakami; M Shoji
Journal:  Neurosci Lett       Date:  1999-12-17       Impact factor: 3.046

5.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease.

Authors:  K R Bales; T Verina; D J Cummins; Y Du; R C Dodel; J Saura; C E Fishman; C A DeLong; P Piccardo; V Petegnief; B Ghetti; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

6.  No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer disease.

Authors:  W K Scott; L H Yamaoka; M P Bass; P C Gaskell; P M Conneally; G W Small; L A Farrer; S A Auerbach; A M Saunders; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Neurogenetics       Date:  1998-03       Impact factor: 2.660

7.  Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polymorphisms and late onset Alzheimer's disease.

Authors:  R Alvarez; V Alvarez; C H Lahoz; C Martínez; J Peña; J M Sánchez; L M Guisasola; J Salas-Puig; G Morís; J A Vidal; R Ribacoba; B B Menes; D Uría; E Coto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

8.  No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression.

Authors:  K Blennow; A Ricksten; J A Prince; A J Brookes; T Emahazion; C Wasslavik; N Bogdanovic; N Andreasen; S Båtsman; J Marcusson; K Nägga; A Wallin; B Regland; H Olofsson; C Hesse; P Davidsson; L Minthon; A Jansson; L Palmqvist; L Rymo
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

9.  Association between angiotensin-converting enzyme gene and late onset Alzheimer's disease in Han chinese.

Authors:  J D Yang; G Feng; J Zhang; Z X Lin; T Shen; G Breen; D St Clair; L He
Journal:  Neurosci Lett       Date:  2000-12-01       Impact factor: 3.046

10.  Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.

Authors:  K M Mattila; J O Rinne; M Röyttä; P Laippala; T Pietilä; H Kalimo; T Koivula; H Frey; T Lehtimäki
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

View more
  20 in total

Review 1.  The leucine-rich repeat superfamily of synaptic adhesion molecules: LRRTMs and Slitrks.

Authors:  Jaewon Ko
Journal:  Mol Cells       Date:  2012-07-04       Impact factor: 5.034

2.  Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects.

Authors:  Steven P Millard; Franziska Lutz; Ge Li; Douglas R Galasko; Martin R Farlow; Joseph F Quinn; Jeffrey A Kaye; James B Leverenz; Debby Tsuang; Chang-En Yu; Elaine R Peskind; Lynn M Bekris
Journal:  Neurobiol Aging       Date:  2013-09-04       Impact factor: 4.673

3.  Angiotensin-converting enzyme gene polymorphisms and risk for sporadic Alzheimer's disease: a meta-analysis.

Authors:  Xue-Bin Wang; Ning-Hua Cui; Jia-Jia Gao; Xue-Ping Qiu; Na Yang; Fang Zheng
Journal:  J Neural Transm (Vienna)       Date:  2014-05-23       Impact factor: 3.575

4.  A general framework for formal tests of interaction after exhaustive search methods with applications to MDR and MDR-PDT.

Authors:  Todd L Edwards; Stephen D Turner; Eric S Torstenson; Scott M Dudek; Eden R Martin; Marylyn D Ritchie
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

5.  Effect of genetic variation in LRRTM3 on risk of Alzheimer disease.

Authors:  Christiane Reitz; Christopher Conrad; Katherine Roszkowski; Robert S Rogers; Richard Mayeux
Journal:  Arch Neurol       Date:  2012-07

6.  acn-1, a C. elegans homologue of ACE, genetically interacts with the let-7 microRNA and other heterochronic genes.

Authors:  Chanatip Metheetrairut; Yuri Ahuja; Frank J Slack
Journal:  Cell Cycle       Date:  2017-09-21       Impact factor: 4.534

7.  Pharmacogenetic Study on the Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on Iranian Alzheimer's Patients.

Authors:  Mahdi Zamani; Masomeh Mohammadi; Hamid Zamani; Alireza Tavasoli
Journal:  Mol Neurobiol       Date:  2015-08-21       Impact factor: 5.590

8.  A cross-validation procedure for general pedigrees and matched odds ratio fitness metric implemented for the multifactor dimensionality reduction pedigree disequilibrium test.

Authors:  Todd L Edwards; Eric Torstensen; Scott Dudek; Eden R Martin; Marylyn D Ritchie
Journal:  Genet Epidemiol       Date:  2010-02       Impact factor: 2.135

Review 9.  The Role of the Renin-Angiotensin System in Amyloid Metabolism of Alzheimer's Disease.

Authors:  Chao-Liang Chou; Hung-I Yeh
Journal:  Acta Cardiol Sin       Date:  2014-03       Impact factor: 2.672

10.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.